List of Excipients in Branded Drug ZIMHI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Adamis Pharmaceuticals	ZIMHI	naloxone hydrochloride	38739-600	HYDROCHLORIC ACID
Adamis Pharmaceuticals	ZIMHI	naloxone hydrochloride	38739-600	SODIUM CHLORIDE
Adamis Pharmaceuticals	ZIMHI	naloxone hydrochloride	38739-600	WATER
USWM LLC	ZIMHI	naloxone hydrochloride	78670-140	HYDROCHLORIC ACID
USWM LLC	ZIMHI	naloxone hydrochloride	78670-140	SODIUM CHLORIDE
USWM LLC	ZIMHI	naloxone hydrochloride	78670-140	WATER
ZMI Pharma Inc	ZIMHI	naloxone hydrochloride	84571-140	HYDROCHLORIC ACID

ZIMHI Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

ZIMHI is a high-dose naloxone hydrochloride autoinjector designed for rapid intramuscular administration in opioid overdose emergencies. Its commercial differentiation depends less on a complex excipient system than on dose strength, device reliability, shelf stability, ease of use, and procurement access. The strongest opportunities are in device-compatible formulation improvements, supply-chain resilience, lower-cost presentations, and market expansion outside the current U.S. emergency-use segment.

What is ZIMHI and how does its formulation work?

ZIMHI contains 5 mg of naloxone hydrochloride in a 0.5 mL single-dose prefilled autoinjector. The product is administered intramuscularly and is intended for use when opioid overdose is suspected, including exposure to potent synthetic opioids such as fentanyl. The FDA approved ZIMHI in October 2021 under NDA 212295.[1]

ZIMHI formulation profile

Attribute	ZIMHI profile
Active ingredient	Naloxone hydrochloride dihydrate
Dose	5 mg naloxone hydrochloride
Fill volume	0.5 mL
Route	Intramuscular
Presentation	Single-dose prefilled autoinjector
Dosage form	Sterile aqueous injection
Preservative strategy	Preservative-free single-dose system
Key excipients	Sodium chloride, hydrochloric acid, water for injection
pH	Approximately acidic range, as specified in the approved labeling
FDA approval	October 2021
NDA	212295
Therapeutic category	Opioid antagonist

The formulation is intentionally simple. Sodium chloride provides isotonicity. Hydrochloric acid adjusts pH. Water for injection is the vehicle. The product does not rely on surfactants, cosolvents, antioxidants, preservatives, or complex buffering systems in the marketed presentation.[1]

This simplicity reduces excipient-related regulatory and toxicological risk. It also limits opportunities for conventional formulation differentiation. Commercial value is concentrated in dose, delivery device, packaging, stability, and distribution rather than in novel excipient chemistry.

What excipients are used in ZIMHI?

ZIMHI’s core excipient system consists of sodium chloride, hydrochloric acid, and water for injection. The formulation uses an acidic aqueous environment to maintain naloxone hydrochloride in a suitable injectable form.[1]

Why sodium chloride is commercially important

Sodium chloride supports tonicity adjustment and helps make the injection more compatible with intramuscular administration. Its use is established across parenteral products, which simplifies regulatory justification and supplier qualification.

The principal commercial issues are:

• pharmaceutical-grade quality;
• endotoxin and bioburden control;
• reliable global supply;
• compatibility with the cartridge, syringe, needle, and autoinjector;
• control of concentration during sterilization and filling.

Because sodium chloride is a commodity excipient, it is unlikely to create a durable patent barrier. Its value lies in manufacturing reliability and cost control.

Why hydrochloric acid is used

Hydrochloric acid adjusts the formulation pH. Naloxone is supplied as a hydrochloride salt, and the acidic aqueous system supports chemical stability and solubility.

The pH adjustment must be controlled tightly because changes can affect:

• naloxone degradation;
• particulate formation;
• container closure compatibility;
• injection-site tolerability;
• device component compatibility;
• extractables and leachables.

A formulation using a stronger buffer could create a different impurity profile or increase the risk of precipitation during long-term storage. For ZIMHI, a low-complexity pH-adjustment approach is commercially defensible because it minimizes inactive-ingredient burden.

Why water for injection is the primary vehicle

Water for injection provides a well-understood parenteral vehicle. Its main commercial risks involve sterile processing, container closure integrity, particulate control, and endotoxin specifications rather than intellectual property.

The aqueous presentation supports rapid drug availability after intramuscular administration. It also allows a compact, ready-to-use product without reconstitution.

How does ZIMHI’s excipient strategy compare with competing naloxone products?

ZIMHI competes with injectable naloxone products, naloxone nasal sprays, and lower-dose autoinjectors. The principal comparison is not excipient complexity. It is the balance among dose, administration route, usability, cost, and repeat-dosing requirements.

Product category	Typical strength	Delivery system	Excipient differentiation	Commercial position
ZIMHI	5 mg/0.5 mL	Intramuscular autoinjector	Low	High-dose emergency rescue
Generic injectable naloxone	Commonly 0.4 mg/mL or 1 mg/mL	Vial, ampule, syringe	Low	Lowest acquisition cost
EVZIO-type autoinjector	0.4 mg/0.4 mL	Intramuscular or subcutaneous autoinjector	Low	Device-led convenience
Narcan nasal spray	4 mg/0.1 mL	Intranasal spray	Device and nasal formulation	Public access and layperson use
KLOXXADO nasal spray	8 mg/0.1 mL	Intranasal spray	Device and nasal formulation	High-dose intranasal rescue

ZIMHI’s 5 mg dose is intended to address overdose situations in which standard doses may be insufficient, particularly where fentanyl or other high-potency opioids are involved. The tradeoff is a more specialized and generally higher-cost delivery system than a vial or nasal spray.

Intranasal products have a larger excipient and device-development opportunity because nasal absorption depends on formulation volume, spray pattern, viscosity, pH, osmolality, and mucosal tolerability. ZIMHI’s intramuscular route has fewer formulation variables but stronger dependence on device operation and user handling.

What formulation patents protect ZIMHI?

ZIMHI’s defensibility is expected to rely primarily on product-specific device, formulation, and delivery claims rather than on the basic use of sodium chloride or hydrochloric acid. Naloxone hydrochloride itself is an established active pharmaceutical ingredient with no meaningful composition-of-matter exclusivity remaining.

Patent categories relevant to ZIMHI

Patent category	Potential protected subject matter	Strategic value
Autoinjector patents	Housing, activation mechanism, needle deployment, dose delivery	High
Container-device integration	Cartridge, syringe, seal, stopper, actuator compatibility	High
Formulation patents	Concentration, pH, stability, impurity control	Moderate
Method-of-use patents	Administration of high-dose naloxone in opioid overdose	Limited to moderate
Packaging patents	Tamper evidence, protective housing, temperature control	Low to moderate
Manufacturing patents	Sterile filling, assembly, device loading	Moderate

The basic excipient combination is unlikely to provide broad exclusivity because sodium chloride, hydrochloric acid, and water for injection are established injectable excipients. A patent estate would be stronger if it claims a specific concentration, pH range, impurity profile, stability result, or device-compatible formulation that is difficult to design around.

How strong is the ZIMHI patent estate?

ZIMHI’s strongest barriers are likely to be device and product-combination claims. A generic manufacturer could reproduce the active ingredient and excipient system relatively easily but would still need to address:

• a 5 mg injectable presentation;
• a reliable single-use autoinjector;
• human-factors requirements;
• sterile manufacturing;
• container closure integrity;
• patent claims covering the device or drug-device combination;
• FDA requirements for an ANDA or other abbreviated pathway.

The commercial strength of the estate depends on claim scope and expiration dates in the current Orange Book and patent records. Formulation claims based only on conventional excipients would generally be narrower and more vulnerable to design-around strategies than mechanical device claims.

What is the FDA and Orange Book status of ZIMHI?

ZIMHI is an FDA-approved prescription drug marketed under NDA 212295. It is a small-molecule naloxone product, not a biologic. Biosimilar regulation therefore does not apply.[1]

Regulatory pathway for competing products

A competing manufacturer could pursue several routes:

1. An ANDA for a therapeutically equivalent naloxone injection or autoinjector, if the product can meet applicable equivalence and device requirements.
2. A 505(b)(2) application for a modified delivery system, different strength, or formulation not readily supported by an existing reference product.
3. A new NDA for a novel naloxone device or formulation with materially different clinical or technical characteristics.
4. A state- or federal-procurement product using a standard vial or prefilled syringe rather than an autoinjector.

For an autoinjector, the device is a central regulatory issue. FDA review can include dose delivery, activation force, needle deployment, robustness, labeling, usability, and performance after storage and environmental stress.

Orange Book considerations

A generic applicant must review current Orange Book listings for NDA 212295 and evaluate any listed patents and regulatory exclusivities. The relevant issues include:

• whether patents are listed against the drug, device, or both;
• expiration dates;
• pediatric exclusivity, if applicable;
• whether a Paragraph IV certification is needed;
• whether the proposed product can omit or alter the patented device configuration;
• whether an ANDA can demonstrate equivalence for the complete drug-device product.

Patent listing status can change through FDA updates, patent expiration, delisting, litigation, or administrative action. The operative commercial analysis should use the current Orange Book entry rather than older product databases.[2]

When does ZIMHI lose exclusivity?

ZIMHI’s FDA approval date was October 2021. Approval alone does not establish a single generic-entry date. Entry timing depends on regulatory exclusivity, listed patents, certification type, litigation, and the ability of a competitor to develop a compliant autoinjector.

The likely exclusivity framework is:

Exclusivity or barrier	Relevance to ZIMHI
New chemical entity exclusivity	Unlikely to apply because naloxone is an established active ingredient
New clinical investigation exclusivity	Possible only for qualifying new clinical studies
Orphan exclusivity	Not apparent from the product’s opioid-overdose indication
Pediatric exclusivity	Only if separately granted
Device patents	Potentially material
Formulation patents	Potentially material but likely narrower
Trade secrets	Relevant to assembly, testing, and manufacturing
Regulatory review	Relevant to product-specific device equivalence

A generic or follow-on product could enter after patent expiry, successful Paragraph IV litigation, settlement terms allowing earlier entry, or a non-infringing design-around. The practical loss-of-exclusivity date is therefore determined by the last enforceable barrier, not by the NDA approval anniversary.

Which companies are challenging ZIMHI?

The competitive threat comes from manufacturers of generic injectable naloxone, nasal naloxone, and alternative autoinjectors. The highest-probability entrants are established injectable manufacturers with sterile fill-finish capacity and device companies with autoinjector platforms.

Competitive groups

• Generic injectable manufacturers: Viatris, Hikma, Fresenius Kabi, Pfizer, and other approved naloxone suppliers.
• Nasal naloxone manufacturers: Emergent BioSolutions and manufacturers developing or supplying generic or authorized nasal products.
• Device specialists: companies with autoinjector platforms, cartridge systems, and human-factors capabilities.
• Public-sector suppliers: manufacturers competing for state, municipal, hospital, correctional, school, and first-responder contracts.

A public Paragraph IV challenge should be distinguished from ordinary competitive entry. A company can compete with a vial, prefilled syringe, or nasal spray without challenging ZIMHI’s patents because those products may not practice the same device claims.

No biosimilar challenge applies because naloxone is a chemically synthesized small molecule.

What patent litigation affects ZIMHI?

The principal litigation risks are likely to involve device claims, drug-device combination claims, and market-entry timing. A Paragraph IV dispute could lead to:

• a 30-month stay of ANDA approval, subject to statutory conditions;
• a negotiated launch date;
• a license or authorized generic arrangement;
• a finding of invalidity, unenforceability, or non-infringement;
• settlement restrictions involving supply, pricing, or product design.

Litigation scenarios

Scenario	Effect on ZIMHI	Effect on entrant
Valid device patent upheld	Delayed entry	Requires later launch or redesign
Patent invalidated	Accelerated entry	Reduces launch uncertainty
Non-infringement finding	Product-specific entry	Preserves ZIMHI claims against other designs
Settlement with licensed entry	Controlled competition	May provide defined launch date
Device redesign	Higher development cost	May avoid patent claims
Vial or nasal alternative	Limited direct patent exposure	Competes on price or usability

A generic product that uses a different delivery mechanism may avoid direct infringement but would not necessarily be therapeutically or commercially equivalent to ZIMHI.

What commercial opportunities exist for ZIMHI excipients?

The excipient opportunity is strongest where it supports device performance, stability, supply resilience, or differentiated regulatory claims.

1. Supply-chain dual sourcing

Sodium chloride, hydrochloric acid, and water for injection are widely available. A qualified second-source strategy can reduce dependence on a single excipient supplier or sterile manufacturing site.

The value lies in:

• lower procurement risk;
• improved negotiating leverage;
• continuity during shortages;
• regional manufacturing;
• reduced shipping exposure;
• faster scale-up for public-sector contracts.

Because the excipients are conventional, the main barrier is comparability and process validation rather than intellectual property.

2. Improved container and device compatibility

Commercial development can target the interaction between the formulation and the autoinjector. Relevant areas include:

• stopper and seal compatibility;
• silicone oil control;
• lubricant migration;
• extractables and leachables;
• glass or polymer cartridge selection;
• particulate reduction;
• long-term dose accuracy;
• performance after temperature cycling.

A formulation that reduces device-material interaction could support a product improvement supplement or a new drug-device presentation.

3. Extended stability

A stable formulation that tolerates higher temperatures or longer storage could improve deployment in ambulances, police vehicles, correctional facilities, schools, shelters, and community distribution programs.

Potential development targets include:

• reduced degradation under elevated temperature;
• lower particulate formation;
• improved color stability;
• better freeze-thaw tolerance;
• longer in-use or field-storage allowances;
• packaging optimized for light and humidity protection.

Any claimed advantage would require stability data and regulatory support. The opportunity is commercially meaningful because naloxone is often stored outside controlled hospital environments.

4. Lower-cost delivery formats

The most important cost opportunity may be a simpler presentation rather than a new excipient. Potential alternatives include:

• prefilled syringes;
• needle-safety syringes;
• unit-dose ampules;
• lower-cost autoinjectors;
• multi-pack emergency kits;
• standard injectable vials for trained responders.

A conventional naloxone injection can compete aggressively on acquisition cost. ZIMHI must justify its premium through ease of use, high dose, rapid deployment, and reduced administration complexity.

5. Reformulation for intranasal or mucosal delivery

An intranasal version would require a separate technical strategy involving spray performance, nasal deposition, mucosal tolerability, and absorption. Candidate excipient categories could include:

• tonicity agents;
• pH modifiers;
• viscosity modifiers;
• solubilizers;
• preservatives, if compatible with the presentation;
• surfactants or absorption-enhancing systems.

This would be a higher-value formulation opportunity than modifying the current intramuscular excipient system, but it would also face direct competition from Narcan and KLOXXADO.

What generic launch risks exist for ZIMHI?

The likely launch risks are concentrated in five areas.

First, a generic manufacturer may avoid the autoinjector entirely and compete with a lower-cost vial or prefilled syringe. That would pressure ZIMHI in hospital and institutional channels.

Second, nasal naloxone has a usability advantage for untrained bystanders because it avoids needles. Public procurement programs may favor nasal products even when ZIMHI has a higher dose.

Third, device manufacturing is more complex than conventional sterile filling. Failures in activation force, needle deployment, dose accuracy, or packaging could delay approval.

Fourth, the formulation itself is easy to reproduce because it uses conventional excipients. Any commercial moat must therefore arise from the device, validated performance, patents, or contracting position.

Fifth, federal and state agencies may prioritize broad access and low price. These procurement policies can shift demand away from premium autoinjectors.

How does ZIMHI compare with Narcan and KLOXXADO?

ZIMHI is differentiated by intramuscular delivery and a 5 mg dose. Narcan uses a 4 mg intranasal dose, while KLOXXADO uses an 8 mg intranasal dose. The nasal products generally have greater layperson usability, while ZIMHI may appeal to professional responders who value a high-dose injectable presentation and standardized autoinjector operation.

Factor	ZIMHI	Narcan	KLOXXADO
Route	Intramuscular	Intranasal	Intranasal
Dose	5 mg/0.5 mL	4 mg/0.1 mL	8 mg/0.1 mL
Needle required	Yes	No	No
Primary differentiation	High-dose autoinjector	Established public-access nasal product	Higher-dose nasal product
Excipient opportunity	Limited	Moderate to high	Moderate to high
Device dependence	Very high	High	High
Generic substitution	Complex for autoinjector	Complex for nasal spray	Complex for nasal spray
Main commercial pressure	Lower-cost injectables and nasal products	Other nasal products	Other nasal products and injectables

What licensing deals could create value?

Potential licensing opportunities include:

• rights to a lower-cost autoinjector platform;
• regional commercialization rights;
• contract manufacturing and device assembly;
• co-development of a temperature-stable formulation;
• public-sector distribution partnerships;
• international licensing for emergency overdose programs;
• authorized generic supply arrangements;
• combination emergency kits containing naloxone and protective equipment.

A licensee with sterile manufacturing and public-health distribution capability could improve access without changing the core excipient system. Device licensing may produce more defensible value than excipient licensing because mechanical architecture and human-factors data are harder to replicate.

What geographic markets offer the best opportunity?

The United States remains the primary market because of the scale of opioid overdose, fentanyl exposure, public naloxone programs, and first-responder distribution. Commercial opportunities also exist in Canada, Europe, Australia, and other markets, but each jurisdiction has different requirements for device approval, prescription status, overdose response, and reimbursement.

Geographic expansion depends on:

• local registration of naloxone;
• recognition of autoinjector devices;
• emergency-use or over-the-counter pathways;
• procurement by governments and hospitals;
• local manufacturing or packaging;
• temperature and transport conditions;
• language-specific human-factors labeling.

A formulation with broader temperature stability could improve international deployment, particularly where cold-chain infrastructure is limited.

Key Takeaways

• ZIMHI contains naloxone hydrochloride in a simple aqueous formulation using sodium chloride, hydrochloric acid, and water for injection.
• The excipient system is conventional and unlikely to create broad standalone exclusivity.
• The stronger commercial barriers are the 5 mg dose, autoinjector design, device integration, human-factors data, and sterile manufacturing.
• ZIMHI is FDA-approved under NDA 212295 and is a small-molecule product, so biosimilar regulation does not apply.
• Generic competition can arise through vials, prefilled syringes, nasal sprays, or non-infringing autoinjectors.
• The most attractive formulation opportunities involve stability, container-device compatibility, particulate control, and supply-chain dual sourcing.
• Intranasal reformulation is a larger potential opportunity but faces established competition from Narcan and KLOXXADO.
• Public procurement, emergency-response contracts, and lower-cost presentations will determine commercial exposure more than excipient novelty.
• Current Orange Book patent listings, Paragraph IV certifications, litigation, and settlement terms control the practical generic-entry timeline.

FAQs

Can ZIMHI’s sodium chloride formulation be patented?

A conventional sodium chloride-based naloxone injection is unlikely to support broad patent protection by itself. Patent value would require a specific concentration, pH, stability profile, impurity limit, device interaction, or manufacturing result.

Is ZIMHI eligible for a biosimilar?

No. ZIMHI contains naloxone hydrochloride, a chemically synthesized small-molecule drug. Competitors would generally use generic-drug, 505(b)(2), or NDA pathways rather than the biosimilar pathway.

Could a generic manufacturer sell naloxone without copying ZIMHI’s autoinjector?

Yes. A company could compete with a vial, prefilled syringe, nasal spray, or different autoinjector, subject to applicable FDA requirements and patent analysis.

Does a preservative-free formulation create a major ZIMHI advantage?

It supports single-dose emergency use and avoids preservative exposure, but it is not by itself a strong commercial moat. The larger advantages are ready-to-use packaging, high dose, and delivery-device operation.

What is the best excipient-development opportunity for a ZIMHI competitor?

The highest-value opportunity is a formulation and container-device system that improves temperature stability, reduces particulates and extractables, and maintains reliable dose delivery in a lower-cost autoinjector or prefilled syringe.

References

1. U.S. Food and Drug Administration. (2021). ZIMHI (naloxone hydrochloride injection) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2020). Product-specific guidances for generic drug development. FDA.

4. U.S. Food and Drug Administration. (2016). General principles for evaluating drug-device combination products. FDA.

5. Centers for Disease Control and Prevention. (2024). Drug overdose deaths in the United States. CDC.

6. U.S. Food and Drug Administration. (2023). Narcan naloxone hydrochloride nasal spray prescribing information. FDA.

7. U.S. Food and Drug Administration. (2023). KLOXXADO naloxone hydrochloride nasal spray prescribing information. FDA.